v3.20.1

Deferred income (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2019
Deferred income |
Schedule of deferred income |
|  |  | December 31,
|  |  | 2019 |  | 2018 |  | 2017
|  |  | (Euro, in thousands)
Deferred income related to contracts |  |  |  |  |  |  |  |  |  |
Gilead collaboration agreement for filgotinib |  |  | € | 780,261 |  | € | 145,798 |  | € | 213,981
Gilead collaboration agreement for drug discovery platform (1) |  |  |  | 2,220,013 |  |  |  |  |  |
AbbVie collaboration for CF |  |  |  |  |  |  | 3,223 |  |  |
Servier collaboration agreement for osteoarthritis |  |  |  |  |  |  |  |  |  | 5,362
Deferred income related to contracts in our fee-for-service segment |  |  |  | 362 |  |  | 471 |  |  | 248
Other deferred income (grants) |  |  |  | 10 |  |  | 309 |  |  | 301
Total deferred income ( long term & current) |  |  | € | 3,000,646 |  | € | 149,801 |  | € | 219,892
(1) This amount comprises an issuance liability for subsequent warrant B of €16,184 thousand.
Schedule of movement in the non-current and current deferred income |
|  |  | Total |  |  | Gilead collaboration agreement for filgotinib |  |  | Gilead collaboration agreement for GLPG1690 |  |  | Gilead collaboration agreement for drug discovery platform (2) |  |  | AbbVie collaboration agreement for CF |  |  | Servier collaboration agreement for osteoarthritis |  |  | Deferred income related to contracts in our fee-for-service segment |  |  | Other
|  |  | (Euro, in thousands)
On Januari 1, 2017 |  | € | 285,612 |  | € | 285,313 |  |  |  |  |  |  |  |  |  |  |  |  |  | € | 47 |  | € | 252
Upfront/license fees received |  |  | 6,000 |  |  |  |  |  |  |  |  |  |  |  |  |  | € | 6,000 |  |  |  |  |  |
Revenue recognition of upfront/license fees |  |  | (71,971) |  |  | (71,333) |  |  |  |  |  |  |  |  |  |  |  | (638) |  |  |  |  |  |
Other movements |  |  | 250 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 202 |  |  | 48
On December 31, 2017 |  |  | 219,892 |  |  | 213,981 |  | € | — |  | € | — |  | € | — |  |  | 5,362 |  |  | 248 |  |  | 300
Reclassified from equity following adoption of IFRS 15 |  |  | 83,220 |  |  | 43,832 |  |  |  |  |  |  |  |  | 44,749 |  |  | (5,362) |  |  |  |  |  |
Upfront received |  |  | 38,874 |  |  |  |  |  |  |  |  |  |  |  | 38,874 |  |  |  |  |  |  |  |  |
Milestones received |  |  | 20,965 |  |  | 12,417 |  |  |  |  |  |  |  |  | 8,548 |  |  |  |  |  |  |  |  |
Revenue recognition of upfront |  |  | (148,985) |  |  | (96,809) |  |  |  |  |  |  |  |  | (52,176) |  |  |  |  |  |  |  |  |
Revenue recognition of milestones |  |  | (64,394) |  |  | (27,623) |  |  |  |  |  |  |  |  | (36,771) |  |  |  |  |  |  |  |  |
Other movements |  |  | 229 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 222 |  |  | 7
On December 31, 2018 |  |  | 149,801 |  |  | 145,798 |  |  | — |  |  | — |  |  | 3,224 |  |  | — |  |  | 471 |  |  | 308
Upfront received and impact of initial valuation of share subscription |  |  | 3,655,416 |  |  | 641,663 |  |  | 666,967 |  |  | 2,346,787 |  |  |  |  |  |  |  |  |  |  |  |
Milestones received |  |  | 49,727 |  |  | 27,317 |  |  |  |  |  |  |  |  | 22,410 |  |  |  |  |  |  |  |  |
Significant financing component |  |  | 6,900 |  |  | 6,900 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition of upfront |  |  | (1,009,663) |  |  | (260,207) |  |  | (666,967) |  |  | (80,918) |  |  | (1,570) |  |  |  |  |  |  |  |  |
Revenue recognition of milestones |  |  | (51,156) |  |  | (27,092) |  |  |  |  |  |  |  |  | (24,064) |  |  |  |  |  |  |  |  |
Catch-up effect on closing date (1) |  |  | 245,883 |  |  | 245,883 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other movements |  |  | (46,262) |  |  |  |  |  |  |  |  | (45,856) |  |  |  |  |  |  |  |  | (109) |  |  | (297)
On December 31, 2019 |  | € | 3,000,646 |  | € | 780,261 |  | € | — |  | € | 2,220,013 |  | € | — |  | € | — |  | € | 362 |  | € | 10
| (1) |  | Following the contract amendment, the revenue recognized for filgotinib for the year ended December 31, 2019 included a negative catch-up effect resulting from the decrease in the percentage of completion applied to previously received upfront and milestones for that program.
The upfront received and the outstanding balance at December 31, 2019 comprise the issuance liabilities for the warrants and the upfront payment allocated to the drug discovery platform. Other movements include the derecognition of warrant issuance liabilities through the share premium account.

X
- Definition Deferred income [abstract] + References No definition available. + Details
Name: | glpg_DeferredIncomeAbstract
Namespace Prefix: | glpg_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of deferred income. + References No definition available. + Details
Name: | glpg_DisclosureOfDeferredIncomeTableTextBlock
Namespace Prefix: | glpg_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of movement in the non-current and current deferred income. + References No definition available. + Details
Name: | glpg_DisclosureOfMovementInNonCurrentAndCurrentDeferredIncomeTableTextBlock
Namespace Prefix: | glpg_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration